Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoTSE:4527 -1.72%92 PEG Ratio is 1.00 as of Jul. 21, 2026, which is 43% below its 10-year median of 1.75. GuruFocus rates TSE:4527 with a GF Score™ of 92/100 and a GF Value™ of 円3,477.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 792 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 57.83% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Rohto Pharmaceutical Co's PEG Ratio or its related term are showing as below:
TSE:4527'
s PEG Ratio Range Over the Past 10 Years
Min: 0.66 Med: 1.75 Max: 250.22
Current: 1
During the past 13 years, Rohto Pharmaceutical Co's highest PEG Ratio was 250.22. The lowest was 0.66. And the median was 1.75.
TSE:4527's PEG Ratio is ranked better than 57.83% of 792
companies
in the Consumer Packaged Goods industry
Industry Median: 1.295
vs TSE:4527: 1.00
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Rohto Pharmaceutical Co (TSE:4527) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co PEG Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Rohto Pharmaceutical Co (TSE:4527) has a PEG Ratio of 1.00 as of Jul. 21, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rohto Pharmaceutical Co and its competitors. This is 43% below median its historical median of 1.75. Over the past decade, Rohto Pharmaceutical Co's PEG Ratio has ranged from 0.66 to 250.22. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #334 out of 792 companies in the Consumer Packaged Goods industry, placing it in the top 42.2%.
Is Rohto Pharmaceutical Co's PEG Ratio too high?
Rohto Pharmaceutical Co's current PEG Ratio of 1.00 is 43% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 250.22. The Consumer Packaged Goods industry median PEG Ratio is 1.30. Rohto Pharmaceutical Co's value of 1.00 is 22.8% below this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #334 out of 792 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's PEG Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #334 out of 792 companies for PEG Ratio. This puts Rohto Pharmaceutical Co in the upper half of its industry. The industry median PEG Ratio is 1.30. Rohto Pharmaceutical Co's value of 1.00 is 22.8% below this benchmark. Historically, Rohto Pharmaceutical Co's own PEG Ratio has ranged from 0.66 to 250.22 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.30, Rohto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Consumer Packaged Goods company?
The median PEG Ratio among Consumer Packaged Goods companies is 1.30, based on 792 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current PEG Ratio of 1.00 is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median PEG Ratio is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current PEG Ratio is 1.00, which is 43% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Significantly Undervalued. The stock's GF Value™ is 円3,477.35, compared to a current price of 円2,435.00 — trading 30% below its estimated fair value. The current PEG Ratio is 1.00, which is 43% below median its 10-year median of 1.75 and 22.8% below the Consumer Packaged Goods industry median of 1.30. Rohto Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current PEG Ratio is 1.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,435.00 is trading 30% below its estimated GF Value™ of 円3,477.35.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
PEG Ratio: 1.00 (43% below median its 10-year median of 1.75)
GF Value™: 円3,477.35 vs. price of 円2,435.00 (30% below fair value)
Industry Position: 22.8% below the Consumer Packaged Goods median (#334 of 792)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for TSE:4527
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
